The market turbulence unleashed by President Donald Trump’s tariff policies will likely evaporate the trickle of biotech IPOs that were expected in 2025, a capital markets expert has told Fierce.
Volatility creates unique opportunities that don’t exist in calm markets, as assets can become mispriced during periods of fear and euphoria. While volatile markets present profit potential, there are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback